- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02529709
The Effect of Meal Composition on Blood Lipids
April 19, 2016 updated by: Meena Shah, Texas Christian University
The Effect of Meal Composition on Blood Lipid Concentrations
The purpose of this study is to see if a high-protein meal leads to a better postprandial (after a meal) blood lipid profile compared to a high-monounsaturated meal.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The effect of a high-protein diet compared to a high-monounsaturated fat diet on fasting lipids is controversial (1,2), In addition, these studies did not examine the effect of a high-protein compared to a high-monounsaturated meal on postprandial lipid concentrations.
Postprandial lipid responses are important to examine since they are associated with heart disease (3,4).
In addition, most individuals in Western countries are in a postprandial state for majority of the day.
The present study will compare the effect of a high-protein meal versus a high-monounsaturated fat meal on postprandial lipid responses.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76129
- Texas Christian University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women ages 18-65 years.
Exclusion Criteria:
- Use of medications or supplements that affect lipid levels, body weight, or blood glucose,
- following a weight loss diet,
- being a vegan,
- smoking,
- heavy alcohol use,
- pregnancy,
- lactation,
- severe depression,
- eating disorders,
- presence of liver, kidney, gastrointestinal, adrenal, or untreated thyroid disease,
- diabetes,
- lactose intolerance,
- documented mal-absorption, or
- bowel surgery that affects absorption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High-protein meal condition
|
The participants will be fed a high-protein meal
|
|
Active Comparator: High-monounsaturated fat meal condition
|
The participants will be fed a high-monounsaturated fat meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Blood lipid concentrations.
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
IL-6
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
TNF-α
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
C-reactive protein
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
GLP-1
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
Insulin
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
Glucagon
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
Glucose
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
|
Leptin
Time Frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Meena Shah, Ph.D., Tzu Chi University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005 Nov 16;294(19):2455-64. doi: 10.1001/jama.294.19.2455.
- Luscombe-Marsh ND, Noakes M, Wittert GA, Keogh JB, Foster P, Clifton PM. Carbohydrate-restricted diets high in either monounsaturated fat or protein are equally effective at promoting fat loss and improving blood lipids. Am J Clin Nutr. 2005 Apr;81(4):762-72. doi: 10.1093/ajcn/81.4.762.
- Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 1987 May;65(1-2):181-9. doi: 10.1016/0021-9150(87)90020-7.
- Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16. doi: 10.1001/jama.298.3.309.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
August 14, 2015
First Submitted That Met QC Criteria
August 19, 2015
First Posted (Estimate)
August 20, 2015
Study Record Updates
Last Update Posted (Estimate)
April 21, 2016
Last Update Submitted That Met QC Criteria
April 19, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TexasCU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Fundación del Caribe para la Investigación BiomédicaNaturmegaNot yet recruitingMixed DyslipidemiaColombia
-
Addpharma Inc.Not yet recruitingMixed DyslipidemiaSouth Korea
-
Daewon Pharmaceutical Co., Ltd.Completed
-
Addpharma Inc.RecruitingMixed DyslipidemiaKorea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Canada, Hungary, New Zealand, Poland
-
Shanghai Argo Biopharmaceutical Co., Ltd.Active, not recruiting
Clinical Trials on High-Protein Condition
-
University of MichiganCompleted
-
University of BirminghamMaastricht UniversityCompletedPhysical ActivityUnited Kingdom
-
University of MiamiThe Craig H. Neilsen FoundationRecruiting
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
University of PittsburghNational Institute on Deafness and Other Communication Disorders (NIDCD); University...Recruiting
-
Hôpital le VinatierNot yet recruiting
-
Hôpital le VinatierRecruiting
-
Western University, CanadaCompleted